We are testing a new treatment called SER-252, designed to help people with Parkinson’s disease who experience ‘OFF’ times during the day. SER-252 is a new long-acting form of apomorphine designed to help reduce OFF periods in patients who are still experiencing OFF episodes despite optimised therapy. ON means medication is working; OFF means symptoms return.
The study will evaluate safety, tolerability, and measure how the drug moves through the body.
Who can take part?
- Are 40–80 years old
- Have Parkinson’s disease and experience daily episodes where your current medications do not work optimally and result in OFF periods (your medication wears off in between doses and your symptoms return)
- Are on a stable medication regimen that includes levodopa doses 3-4 times each day
Your doctor will confirm if you meet all requirements for the study.
What does participation involve?
- Stay in a clinic for 7 days so doctors can monitor you closely
- Receive one dose of the study drug, or placebo (inactive substance)
- Return for a follow-up visit about 1 week later
- Travel and hotel costs will be covered for you and your caregiver
Where is the study happening?
CMAX – CMAX is currently recruiting subjects for this study.
- Address: 21-24 North Terrace, Adelaide, South Australia 5000
- Contact Name: CMAX Clinical Research
- Phone: +61 8 7088 7900
- Email: [email protected]
Monash House Research – is expected to begin recruitment by end of March 2026.
- Address: 271 Clayton Road, Clayton, Victoria, 3168
- Contact Name: Monash House Research Centre
- Phone: +61 3 8394 0700
- Email: [email protected]
Three to five more Australian sites will begin recruitment soon, and details will be shared at a later date.
What should you do next?
• Talk to your neurologist about this trial
• Print this page and take it to your appointment
• Contact research sites directly
| ETHICS Number | NCT07422675 |
|---|
Donations
Your donation helps us to achieve our core business, to improve the lives of people affected by Parkinson’s in Australia through national advocacy, raising awareness and connecting people living with Parkinson’s, their families and carers, researchers and health professionals in the Parkinson’s community.
